ROYALTY PHARMA ACQUIRES REMAINING ROYALTY INTEREST IN ROCHE’S EVRYSDI FOR $240 MILLION AND POTENTIAL MILESTONES
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.